Innate Pharma - ADR Forecast, price target & analysts
Innate Pharma - ADR Target price 2025 - Analyst rating & recommendation
Innate Pharma - ADR Classifications & Recommendation:
Innate Pharma - ADR Price Target
| Target Price | $6.80 |
| Price | $2.16 |
| Potential |
214.61%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Innate Pharma - ADR 2026 .
The average Innate Pharma - ADR target price is $6.80.
This is
214.61%
register free of charge
$10.31
377.27%
register free of charge
$2.94
36.09%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Innate Pharma - ADR to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Innate Pharma - ADR stock has an average upside potential 2026 of
214.61%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 14.78 | 106.03 |
| 75.68% | 618.86% | |
| EBITDA Margin | -392.76% | 11.11% |
| 2,590.87% | 102.83% | |
| Net Margin | -391.88% | 33.82% |
| 2,587.88% | 108.63% |
5 Analysts have issued a sales forecast Innate Pharma - ADR 2025 . The average Innate Pharma - ADR sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Innate Pharma - ADR EBITDA forecast 2025. The average Innate Pharma - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Innate Pharma - ADR Analysts have issued a net profit forecast 2025. The average Innate Pharma - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.71 | 0.43 |
| 545.45% | 160.56% | |
| P/E | 5.05 | |
| EV/Sales | 1.87 |
6 Analysts have issued a Innate Pharma - ADR forecast for earnings per share. The average Innate Pharma - ADR EPS is
This results in the following potential growth metrics and future valuations:
Innate Pharma - ADR...
Current Innate Pharma - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | May 07 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Dec 08 2024 |
| BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jul 14 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Mar 27 2025 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Dec 08 2024 |
|
Locked
BRYAN GARNIER:
Locked
➜
Locked
|
Nov 12 2024 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Nov 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
